The Future of Drug Discovery: Who Decides Which Diseases to Treat?

The Future of Drug Discovery: Who Decides Which Diseases to Treat?

Volumn , Issue , 2013, Pages 1-346

  Bartfai, Tamas ^a   Lees, Graham V ^b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b Corpus Alienum Oy ^*  (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84880913356     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/C2012-0-03143-2     Document Type: Book

References (55)

1. Li R, Zhang P, Barker LE, Chowdhury FM, & Zhang X (2010) Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care. Aug; 33(8):1872-1894.
2. Bartfai T & Lees GV (2011) Pharma TARP: a troubled asset relief program for novel, abandoned projects in the pharmaceutical industry. TheScientificWorldJournal. Feb 14;11:454-457.
3. Bartfai T & Lees GV (2006) Drug Discovery: from Bedside to Wall Street. Elsevier/Academic Press: Amsterdam.
4. Nissen SE & Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. June 14; 356:2457-2471.
5. Novartis' Tasigna beats Glivec in leukemia study - FiercePharma http://www.fiercepharma.com/story/novartis-tasigna-beats-glivec-leukemia-study/2009-12-08#ixzz0ziK24bxZ
6. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000666/WC500021282.pdf
7. http://www.nhlbi.nih.gov/whi/index.html
8. http://www.framinghamheartstudy.org/about/index.html
9. http://www.framinghamheartstudy.org/participants/original.html
10. http://www.framinghamheartstudy.org/about/milestones.html54
11. http://www.framinghamheartstudy.org/participants/pr/10_0511.html
12. Shields WD & Pellock JM (2011) Vigabatrin 35 years later-from mechanism of action to benefit-risk considerations. Acta Neurol Scand. 124 (Suppl. 192): 1-4.
13. Bartfai T and Lees GV (2006) Drug Discovery: from Bedside to Wall Street. Elsevier/Academic Press: Amsterdam.
14. http://www.rarediseases.org/
15. Bartfai T and Lees, GV (2006) Drug Discovery: from Bedside to Wall Street. Elsevier/Academic Press: Amsterdam, p. 58.
16. http://officeofbudget.od.nih.gov/approp_hist.html
17. http://www.fiercepharma.com/special-reports/top-10-generic-drug-companies-2010#ixzz1M9SykLp8
18. American Diabetes Association (2008) Economic costs of diabetes in the U.S. in 2007. Diabetes Care. Mar; 31(3):596-615.
19. Levy S et al. (2007) The diploid genome sequence of an individual human. PLoS Biol. Sep 4; 5(10):e254.82
20. Venter JC et al. (2001) The sequence of the human genome. Science. Feb 16; 291(5507):1304-1351.
21. Lander, ES et al. (2001) Initial sequencing and analysis of the human genome. Nature. Feb 15; 409(6822):860-921.84
22. Wheeler DA et al. (2008) The complete genome of an individual by massively parallel DNA sequencing. Nature. Apr 17; 452(7189):872-876
23. Watson JD and Crick FHC (1953) A structure for deoxyribose nucleic acid. Nature. Apr 25; 171, 737-738 .
24. http://www.nature.com/news/2007/070528/full/news070528-10.html88
25. http://www.nature.com/news/2008/080416/full/452788b.html
26. http://www.multivu.com/mnr/56128-banner-alzheimer-s-institute-genentech-nih-prevention-trial-genetics
27. http://www.fiercebiotech.com/special-reports/top-10-phase-iii-failures-2010
28. http://en.wikipedia.org/wiki/Evergreening
29. http://www.aacr.org/home/public--media/science-policy--government-affairs/aacr-cancer-policy-monitor/aacr-cancer-policy-monitor---february-2010/white-house-proposes-to-increase-nih-budget-by-$1-billion.aspx2
30. http://officeofbudget.od.nih.gov/pdfs/FY12/Volume%201%20-%20Overview.pdf
31. http://www.fiercebiotech.com/story/10-pharma-giants-form-nonprofit-gang-common-rd-foes/2012-09-19
32. http://www.fiercebiotech.com/story/bdo-biotech-rd-spending-hiring-rebounds-revenue-climbs-big-companies/2012-09-25
33. http://www.fiercebiotech.com/press-releases/biotech-industry-rd-spending-jumps-five-percent-2011-bdo-study-finds
34. http://www.turns.ucla.edu/
35. Hollis LJ (2010) Report: U.S. cancer trials are in a state of crisis, FierceBiotech, April 16, http://www.fiercebiotech.com/story/report-u-s-cancer-trials-are-state-crisis/2010-04-16
36. http://books.nap.edu/openbook.php?record_id=12879.
37. Carroll J (2010) FDA proposes controversial release of complete response letters, FierceBiotech, May 20, http://www.fiercebiotech.com/story/fda-proposes-controversial-release-complete-response-letters/2010-05-20#ixzz20un9qyUK.
38. http://www.bloomberg.com/news/2013-01-07/roche-comments-may-mean-no-illumina-deal-in-near-term.html
39. http://www.infogrok.com/index.php/pharmaceutical/diagnocure_wins_us_approval_for_colorectal_cancer_staging_test.html
40. http://www.diagnocure.com/docs/news/297.2010-08-03_DOL_receives_NY_State_Laboratory_Permit.pdf
41. http://www.diagnocure.com/docs/news/314.2011-01-20_-_Positive_Initial_Results_from_Colon_Cancer_GCC_Assay_Study_-Final.pdf
42. http://www.kff.org/insurance/snapshot/oecd042111.cfm
43. http://www.milkeninstitute.org/publications/publications.taf?function=detail&ID=38801018&cat=resrep
44. http://www.milkeninstitute.org/publications/publications.taf?function=detail&ID=38801020&cat=ResRep
45. Méndez C and Salas JA (2001) Altering the glycosylation pattern of bioactive compounds. Trends Biotechnol. Nov; 19(11):449-456.
46. http://investor.bms.com/phoenix.zhtml?c=106664&p=irol-newsArticle_print&ID=494936&highlight=
47. http://www.nice.org.uk/newsroom/features/measuringeffectivenessandcosteffectivenesstheqaly.jsp
48. http://www.nice.org.uk/newsroom/features/measuringeffectivenessandcosteffectivenesstheqaly.jsp
49. http://v/VAV.ema.europa.eu/
50. Grogan K. (2011) M&A strategy has failed miserably-Burrill Online PharmaTimes, April 13, 2011, http://www.pharmatimes.com/Article/11-04-13/M_A_strategy_has_failed_miserably_-_Burrill.aspx
51. Carroll, John (2011) Sanofi chief outlines R&D, biotech investment strategy, FierceBiotech 12 April 2011, http://www.fiercebiotech.com/story/sanofi-chief-outlines-rd-biotech-investment-strategy/2011-04-12.
52. Carroll, John (2011) Sanofi-Aventis-he world's biggest R&D spenders, FierceBiotech, 8 March, 2011, http://www.fiercebiotech.com/special-reports/worlds-biggest-rd-spenders/sanofi-aventis-worlds-biggest-rd-spenders.
53. Carroll, John (2011) Will Pfizer divest a big chunk of its operations?, FierceBiotech, 14 March, 2011, http://www.fiercebiotech.com/story/will-pfizer-divest-big-chunk-its-operations/2011-03-14.
54. Randall, Tom (2009) Sanofi Lands Cancer Drug by Paying $500 Million for 18 People, Bloomberg 1 June 2009, http://www.bloomberg.com/apps/news?pid=newsarchive&sid=aiit0O.KTlIE&refer=us.
55. Bartfai T and Lees GV (2006) Drug Discovery: from Bedside to Wall Street. Elsevier/Academic Press: Amsterdam.